OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	168
Giant cell arteritis: update on pathogenesis and clinical implications	71
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	57
Editorial introduction	51
Current approach to muscle imaging in myositis	46
Current views on lupus in children	45
Urticarial vasculitis	44
Editorial introductions	36
Axial spondyloarthritis guidelines – aiming for maximum impact	33
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	31
Osteoporosis epidemiology using international cohorts	31
Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden	29
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	29
The gut microbiota in spondyloarthritis: an update	28
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	27
Rheumatoid arthritis – the challenge of heterogeneity	26
A comprehensive review of systemic sclerosis–primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype	26
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	26
Editorial introductions	24
Updates on translational and clinical research in systemic sclerosis	21
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	20
Editorial introductions	20
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	19
Ribosome dysfunction in osteoarthritis	19
Update on gout management: what is old and what is new	18

Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	17
Editorial introductions	17
Editorial introduction	16
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	16
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	16
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	16
Defining and managing flares in axial spondyloarthritis	16
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	14
Health inequities in the rheumatic diseases of childhood	14
Epidemiology of myositis	14
Editorial introductions	14
Animal models of vasculitis	13
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	13
Gout and the COVID-19 pandemic	13
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	12
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	12
New developments related to lung complications in pediatric rheumatic disease	11
Insights into the molecular landscape of osteoarthritis in human tissues	11
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	11
Editorial introductions	11
Biomarker discovery in psoriatic disease	11
Editorial introductions	11
Environmental and occupational contributors to autoimmune, inflammatory, and musculoskeletal rheumatic disease: a review of emerging evidence and clinical implications	11
Diagnosis and management of primary heart involvement in systemic sclerosis	11
Vasculitis and the NLRP3 inflammasome	10
Heart involvement in systemic sclerosis: emerging concepts	10
Management of postinfectious inflammatory arthritis	10
Investigating gout flares: beyond a definition	10
Emerging biologic therapies for systemic lupus erythematosus	10
Editorial introduction	10
AI am the future: artificial intelligence in pediatric rheumatology	10
Exploring challenges in the management and treatment of inclusion body myositis	9
Epidemiology of osteoarthritis: literature update 2022–2023	9
Advances in the diagnosis and treatment of Sjögren disease	9
The association of Behçet's syndrome with HLA-B51 as understood in 2021	9
Update on streptococcal-associated rheumatic disease	8
The contribution of endothelial cells to tissue fibrosis	8
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	8
Current management of giant cell arteritis and its complications	8
Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications	8
Animal models in systemic sclerosis: an update	7
Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results	7
What have we learned about systemic sclerosis from the EUSTAR database?	7
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	7
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	7
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	7
Treatment of systemic vasculitis	7
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	7
Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis	7
Calcinosis in systemic sclerosis	7

What are mice teaching us about psoriatic arthritis?	6
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	6
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	6
Clinical endpoints in myositis: challenges and ways forward	6
New therapies in anti-MDA5 antibody-positive dermatomyositis	6
Osteoarthritis gene therapy in 2022	6
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024	6
Go or no-go for treat-to-target in axial spondyloarthritis?	6
Biomarkers in juvenile idiopathic arthritis: towards precision diagnosis and personalized therapy?	6
Describing calcium pyrophosphate deposition: undoing the tower of Babel!	6
Update on muscle imaging in myositis	6
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	6
Epidemiology of systemic vasculitis	6
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis	6
Should CAR-T cells be used as monotherapy?	5
Scleroderma autoantibodies in guiding monitoring and treatment decisions	5
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases	5
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	5
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	5
Contribution of keratinocytes to dermal fibrosis	5
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	5
Rethinking spondyloarthritis: beyond lumping and splitting	5
Quo vadis reactive arthritis?	5
Recent advances in immunometabolism in rheumatic diseases	5
Renal disease in pediatric rheumatology	5
Calcinosis in systemic sclerosis	5
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	5
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	5
Advances in understanding and examining lymphatic function: relevance for understanding autoimmunity	4
Updates in juvenile dermatomyositis: pathogenesis and therapy	4
Disease modification in axial spondyloarthritis – still a controversy?	4
Advances in osteoarthritis imaging	4
Methods for objective assessment of skin involvement in systemic sclerosis	4
Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus – focus on juvenile-onset systemic lupus erythematosus	4
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	4
Editorial introduction	4
Drug therapy in juvenile spondyloarthritis	4
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies	4
Omics studies in Behçet's disease	4
Editorial introduction	4
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives	4
Editorial myositis and myopathies	4
Vaccination updates and special considerations for systemic lupus erythematosus patients	3
Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities	3
Understanding psoriatic disease at single-cell resolution: an update	3
The impact of omics research on our understanding of osteoarthritis and future treatments	3
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	3
Is osteoarthritis a mitochondrial disease? What is the evidence	3
Human leucocyte antigen-B27 testing in clinical practice: a global perspective	3
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights	3
An update on inflammation in antiphospholipid syndrome	3
Regulatory T cells and systemic vasculitis	3
Updates in uricase therapy for gout	3
Harnessing artificial intelligence to advance insights in systemic sclerosis skin and lung disease	3
SGLT-2 inhibitors: new horizons for rheumatologists	3